Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.
about
Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brainFactor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.The diversity of the immune response to the A2 domain of human factor VIIIAcidic residues C-terminal to the A2 domain facilitate thrombin-catalyzed activation of factor VIII.Storage and regulated secretion of factor VIII in blood outgrowth endothelial cellsThe sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII.Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies.Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional protein.Intracellular retention of a factor VIII protein with an Arg2307-->Gln mutation as a cause of haemophilia A.The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa.Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry.Enhanced secretory ability for the human factor VIII light chain produced in baculovirus-infected insect cells.Dissimilar interaction of factor VIII with endothelial cells and lipid vesicles during factor X activation.A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII.Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function.Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity.Epitope mapping of factor VIII inhibitor antibodies of Chinese origin.Hypothesis for the control of clotting factor VIII inhibitory antibodies by decreasing potency of helper T-cell-recognized epitopes in factor VIII.Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain.Detection and IgG subclass analysis of antibodies to factor VIII in multitransfused haemophiliacs and healthy individuals.Proteolytic cleavage of factor VIII heavy chain is required to expose the binding-site for low-density lipoprotein receptor-related protein within the A2 domain.
P2860
Q34189547-16B3807D-6CD7-472C-9D89-2BC05CEA3FA0Q34666433-44A24A86-77EA-4A4F-B618-66B5CA83D378Q35611898-FA2268FD-BE30-4725-BABE-C74ADC021E0EQ36743356-7FE59031-159F-4BCF-BCF4-B6D631408510Q37010903-427A1EFF-2921-4414-9CE6-0631921B8E07Q37175588-63500FC1-DB35-4736-8C45-55105FA64FE0Q38362540-A8D04A77-B340-4998-8C67-B1530D902186Q38792889-4B487D2F-9C4B-40BC-9339-E949E9D74500Q39733186-BCEBC694-2A9A-4020-974C-34705E90DAD4Q40063048-9874C400-F016-4C98-BD9A-39D43E44DD54Q40555265-C4163555-DB40-4CA7-9AFD-ECDDFC0EA603Q41167453-94950102-8A11-468F-AC8A-EF479988FC03Q41695401-2AFC4919-D644-4755-8E1F-A83856384689Q41828726-A3D306B5-C646-40FF-99CF-08ED9E35A836Q42036652-067ED44F-FA27-4ECC-86ED-1E0EBE27AA90Q42064982-FA074891-0703-489C-9185-540930468008Q42986413-529496A9-1B2E-4878-80EB-FC8B00482F18Q43405759-056B2A19-E09A-4F67-9E50-FCD48C30D25DQ44274593-F8B934F9-E121-4183-9B1C-1626D5B05E30Q45861953-30A1226D-3536-41E1-95B2-B61F74BCB586Q45873498-403B2F40-9EE9-4A91-AF26-1FD8848E7E15Q45878467-8E9186BA-B648-4CAC-9E2E-C5551D59339EQ45878768-88FD21A4-5A18-4AB6-8AB2-A851B2CA3581Q45881688-CD9B81AC-52AA-427C-A3EA-07292D845721Q45886534-476E8E34-D7F4-4378-B714-3E1D46DA8BEBQ53611730-0001B912-8931-429B-9097-DB8607E985CD
P2860
Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Inhibition of human coagulatio ...... mbinant factor VIII fragments.
@en
type
label
Inhibition of human coagulatio ...... mbinant factor VIII fragments.
@en
prefLabel
Inhibition of human coagulatio ...... mbinant factor VIII fragments.
@en
P2093
P2860
P356
P1433
P1476
Inhibition of human coagulatio ...... mbinant factor VIII fragments.
@en
P2093
De Bruin J
De Keyzer-Nellen MJ
Groenen-Van Dooren MM
Pannekoek H
Van Mourik JA
Verbeet MP
P2860
P304
P356
10.1042/BJ2630187
P407
P577
1989-10-01T00:00:00Z